Navigation Links
China Sky One Medical Receives GMP Re-Certification
Date:5/27/2010

HARBIN, China, May 27 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that its Tian Long Pharmaceutical Company ("Tian Long") subsidiary successfully obtained renewal of its Good Manufacturing Practices Certificate for Pharmaceutical Products ("GMP Certificate") from the State Food and Drug Administration (SFDA) in China. The new certificate will be valid until May 2015.

According to the National Medicine Administration Law of the PRC, all pharmaceutical manufacturers are required to renew their GMP Certificates every five years. SFDA's examination committee visited Tian Long in April to review its supply chain management practices, including quality control system test, inspect its GMP management process, production records for its five production lines, quality test record and laboratory management.

"Given the extensive scope of the inspection and examination, we are very proud to pass the examination in just one round and successfully renewed the GMP Certificate for Tian Long," said Mr. Yan-qing Liu, Chairman and CEO of China Sky One Medical. "China Sky One Medical has built a solid track record of adhering to the highest quality control standards, thanks to our talented and dedicated executives and professional teams in the quality control and production departments."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio-Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the renewal of GMP Certificate. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

    For more information, please contact:

    China Sky One Medical, Inc.
     Mr. Stanley Hao, CFO
     Tel:   +86-451-8703-2617
     Email: stanleyhao@cski.com.cn

    Investor Relations Contact:
     CCG Investor Relations
     Ms. Lei Huang, Account Manager
     Tel:   +1-646-833-3417
     Email: lei.huang@ccgir.com

     Ms. Mabel Zhang, Vice President
     Tel:   +1-310-954-1353
     Email: mabel.zhang@ccgir.com
     Web:   http://www.ccgirasia.com


'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dehaier Medical Systems Continues Product Line Expansion. Signs Exclusive Distribution Agreement with HEYER Medical for Respiratory Products in China
2. China BCT Reports First Quarter 2010 Results
3. China-Biotics Provides Updates on Qingpu New Facility and Chinese Probiotics Market
4. OriGene Technologies, Inc. to Build the Worlds Largest TrueMAB(TM) Monoclonal Antibody Facility in Wuxi, China
5. China Biologic Products Schedules Conference Call to Discuss First Quarter 2010 Results
6. Renhuang Pharmaceuticals Exhibits All-Natural Products at the 63rd PHARMACHINA Fair
7. China Pharma Holdings, Inc. CEO to Speak at Brean Murray, Carret & Co. 2010 Life Sciences Summit
8. China Sky One Medical Provides Sales Forecast for 13 New Products
9. China Sky One Medical Attended Import and Export Fair to Enhance International Growth Opportunity
10. Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd.
11. China Pharma Holdings, Inc. Reports First Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... In a list published by the Boston ... 76 fastest-growing private companies; a small percentage of the state's 615,000+ small businesses. The ... percent change in revenue from 2012 to 2015. , As this award ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... , the sensor and data driven conferences, will take place on June 7-8, 2016, at the ... UnitedHealth's Vidya Raman-Tangella on incorporating technology -- including AR/VR, machine learning, apps, robotics and ...
(Date:5/3/2016)... ... May 03, 2016 , ... Nashville Fertility ... laboratories. A contingency of reproductive endocrinologists, including Dr. George Hill at ... and to help them build families. , Ovation Fertility is a nationwide network ...
(Date:5/2/2016)... ... May 02, 2016 , ... F.E.E.D. Co., the Feline Environmental ... revolutionary, veterinarian-designed product for indoor cats. The NoBowl Feeding System replaces the bowl ... the way nature intended. NoBowls make cats happy and healthy. , Since being ...
Breaking Biology Technology:
(Date:3/9/2016)... , March 9, 2016 This BCC ... future states of the RNA Sequencing (RNA Seq) market ... such as instruments, tools and reagents, data analysis, and ... various segments of the RNA-Sequencing market such as RNA-Sequencing ... Identify the main factors affecting each segment and forecast ...
(Date:3/8/2016)... 8, 2016   Valencell , the leading ... it has secured $11M in Series D financing. ... new venture fund being launched by UAE-based financial ... existing investors TDF Ventures and WSJ Joshua Fund. ... its triple-digit growth and accelerate its pioneering innovation ...
(Date:3/3/2016)... SOTO, Kansas , March 3, 2016 ... Oncimmune,s Early CDT®-Lung, a blood test to aid ... cancer Early CDT®-Lung test to its clients ... Early CDT®-Lung test to its clients which include ... a leader in early cancer detection, today announced a ...
Breaking Biology News(10 mins):